alendronate has been researched along with lovastatin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Benford, HL; Coxon, FP; Rogers, MJ; Russell, RG | 1 |
| Fisher, JE; Halasy, JM; Hughes, DE; Luckman, SP; Masarachia, PJ; Reszka, AA; Rodan, GA; Rogers, MJ; Russell, RG; Wesolowski, G | 1 |
| Andela, VB; O'Keefe, RJ; Pirri, M; Puzas, EJ; Rosenblatt, JD; Rosier, RN; Schwarz, EM | 1 |
| Chihara, K; Inoue, Y; Kaji, H; Naito, J; Sowa, H; Sugimoto, T | 1 |
| Cottrell, JA; Gundlapalli, R; Kapadia, R; O'Connor, JP; Schachter, D; Vales, FM; Wadsworth, S | 1 |
| Crovella, S; De Leo, L; Decorti, G; Marcuzzi, A; Pontillo, A; Tommasini, A | 1 |
2 review(s) available for alendronate and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The mevalonate synthesis pathway as a therapeutic target in cancer.
Topics: Acute-Phase Proteins; Alendronate; Alkyl and Aryl Transferases; Animals; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Neoplasms; Polyisoprenyl Phosphates; Tumor Cells, Cultured | 2003 |
8 other study(ies) available for alendronate and lovastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs.
Topics: Alendronate; Animals; Apoptosis; Carbon Radioisotopes; Caspase 3; Caspases; Cell Line; Cycloheximide; Diphosphonates; Enzyme Activation; Enzyme Inhibitors; Lovastatin; Macrophages; Mevalonic Acid; Mice; Protein Biosynthesis; Protein Synthesis Inhibitors | 1998 |
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Topics: Alendronate; Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Cholesterol; Clodronic Acid; Diterpenes; Enzyme Activation; Farnesol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Osteoclasts; Protein Kinases; Rabbits; Skull; Squalene | 1999 |
Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway.
Topics: Alendronate; Animals; Apoptosis; Cell Line; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Osteoblasts; Quinolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Simvastatin; Smad3 Protein; Transforming Growth Factor beta | 2008 |
Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Femur; Lovastatin; Male; Omeprazole; Organ Size; Osteogenesis; Rats; Rats, Sprague-Dawley; Wound Healing; X-Ray Microtomography | 2010 |
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Topics: Acyclic Monoterpenes; Alendronate; Animals; Anti-Inflammatory Agents; Cell Line; Child; Child, Preschool; Cholesterol; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inflammation Mediators; Lovastatin; Male; Mevalonate Kinase Deficiency; Mice; Monocytes; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Polyenes; Polyisoprenyl Phosphates; Polyunsaturated Alkamides; Pyridines; Quinolones; Terpenes | 2011 |